sleep apnea and tirzepatide GLP-1 medication is known to improve apnea, but not all patients benefit equally. In a new study, presented at #ATS2026, Scott Sands, PhD, associate professor of medicine at Brigham Sleep Apnea Reduced in People

One study published in The New England Journal of Medicine found that participants who took Semaglutide lost an average of 14.9% of their body weight over a period of one year, compared to 2.4% in the placebo group

And through education, support, and smart medical strategies, we help our patients better understand whats realistic, whats working behind the scenes, and how to move forward with a plan that actually fits their life

Research has linked it to improvements in memory, processing speed, and attention

Semaglutide targets one hormone (GLP-1)

and Hansen LS

20 mg in female arousal studies Subcutaneous injection: 0.75 mg, 1.25 mg, and 1.75 mg in Phase 2-3 female HSDD trials FDA-approved dose: 1.75 mg subcutaneously as needed, at least 45 minutes before sexual activity Important: These are doses from completed clinical trials